<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583308</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 053-15</org_study_id>
    <nct_id>NCT02583308</nct_id>
  </id_info>
  <brief_title>Impact of the Subglottic Secretions Drainage on the Tracheal Secretions Colonisation</brief_title>
  <official_title>Impact of the Subglottic Secretions Drainage on the Tracheal Secretions Colonisation: an Ancillary Study of the DEMETER Trial (NCT02515617)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Meta-analysis provide evidence for the benefit of the subglottic secretions drainage (SSD) to
      reduce the occurrence of Ventilator-Associated Pneumonia (VAP). Nevertheless, the diagnosis
      of VAP is widely considered as subjective and prone to both false-positive and false negative
      assignments. In ths way, the impact of SSD remains controversial and its use limited in
      Intensive Care Units. The DEMETER study assessing the medico-economical impact of the the
      subglottic secretions drainage (NCT02515617) provides the opportunity to evaluate the
      dynamics of tracheal colonisation with and without the realisation of SSD. This evaluation
      would reinforce the results observed during the DEMETER study in considering the adjudicated
      VAP incidence.

      This ancillary study will be performed in 14 centers participating to the DEMETER study
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of pseudomonas aeruginosa presence in tracheal secretions according to the study group.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of staphylococcus aureus presence in tracheal secretions according to the study group.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of enterobacteria presence in tracheal secretions according to the study group.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of streptococcus pneumoniae presence in tracheal secretions according to the study group.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of haemophilus influenzae presence in tracheal secretions according to the study group.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of stenotrophomonas maltophilia presence in tracheal secretions according to the study group.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acinetobacter baumannii presence in tracheal secretions according to the study group.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of other non-fermenting gram negative bacilli presence in tracheal secretions according to the study group.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of pseudomonas aeruginosa presence in subglottic secretions during the period with endotracheal tubes allowing SSD.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of staphylococcus aureus presence in subglottic secretions during the period with endotracheal tubes allowing SSD.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of enterobacteria presence in subglottic secretions during the period with endotracheal tubes allowing SSD.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of streptococcus pneumoniae presence in subglottic secretions during the period with endotracheal tubes allowing SSD.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of haemophilus influenzae presence in subglottic secretions during the period with endotracheal tubes allowing SSD.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of stenotrophomonas maltophilia presence in subglottic secretions during the period with endotracheal tubes allowing SSD.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acinetobacter baumannii presence in subglottic secretions during the period with endotracheal tubes allowing SSD.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of other non-fermenting gram negative bacilli presence in subglottic secretions during the period with endotracheal tubes allowing SSD.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Ventilator-associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Period with endotracheal tubes not allowing SSD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period with endotracheal tubes allowing SSD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tubes not allowing SSD</intervention_name>
    <description>In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure</description>
    <arm_group_label>Period with endotracheal tubes not allowing SSD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tubes allowing SSD</intervention_name>
    <description>In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.</description>
    <arm_group_label>Period with endotracheal tubes allowing SSD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Invasive mechanical ventilation delivered via an endotracheal tube and expected to be
             required more than 24 hours

          -  Intubation performed in units in which the specific endotracheal tube allowing the
             subglottic secretions drainage (SSD) will be available during the SSD period of the
             trial

          -  Information delivered

        Exclusion Criteria:

          -  Previous inclusion in the study

          -  Patients moribund at the Intensive Care Unit admission

          -  Pregnant, parturient or breast-feeding woman

          -  Patient hospitalized without consent and/or deprived of liberty by court's decision

          -  Patient under guardianship or curators

          -  Lack of social insurance

          -  Concomitant inclusion in a trial on VAP prevention

          -  Patient with no comprehension of the French language
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude LACHERADE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD VENDEE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Claude LACHERADE, MD</last_name>
    <phone>33 2 51 44 60 87</phone>
    <email>jean-claude.lacherade@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU André Vésale</name>
      <address>
        <city>Montigny-le-Tilleul.</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Piagnerelli, MD, PhD</last_name>
      <phone>32 71 92 21 25</phone>
      <email>michael.piagnerelli@chu-charleroi.be</email>
    </contact>
    <contact_backup>
      <last_name>Dominique Fameree, MD</last_name>
      <email>dominique.fameree@chu-charleroi.be</email>
    </contact_backup>
    <investigator>
      <last_name>Dominique Fameree, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Sirodot, MD</last_name>
      <phone>33 4 50 63 63 04</phone>
      <email>msirodot@ch-annecygenevois.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stephane Bland, MD</last_name>
      <phone>33 4 50 63 63 34</phone>
      <email>sbland@ch-annecygenevois.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Stephane Bland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Pajot, MD</last_name>
      <phone>33 1 34 23 14 45</phone>
      <email>olivier.pajot@ch-argenteuil.fr</email>
    </contact>
    <contact_backup>
      <last_name>Françoise Le Turdu, MD</last_name>
      <phone>33 1 34 23 13 04</phone>
      <email>francoise.leturdu@ch-argenteuil.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Françoise Le Turdu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal des Portes de l'Oise</name>
      <address>
        <city>Beaumont-sur-Oise</city>
        <zip>95260</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric Cleophax, MD</last_name>
      <phone>33 1 39 37 15 20</phone>
      <email>cedric.cleophax@ch-pontoise.fr</email>
    </contact>
    <contact_backup>
      <last_name>Geneviève Blanchard, MD</last_name>
      <email>genevieve.blanchard@ch-pontoise.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Geneviève Blanchard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chd Vendee</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie DESROYS DU ROURE, MD</last_name>
      <email>valerie.desroysduroure@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Docteur Schaffner</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Thevenin, MD</last_name>
      <phone>33 3 21 69 12 34</phone>
      <email>dthevenin@ch-lens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sylvie Ledru, MD</last_name>
      <email>sledru@ch-lens.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sylvie Ledru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Bellec, MD</last_name>
      <phone>33 5 63 92 81 47</phone>
      <email>f.bellec@ch-montauban.fr</email>
    </contact>
    <contact_backup>
      <last_name>Frédéric Février, MD</last_name>
      <email>f.fevrier@ch-montauban.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Frédéric Février, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Wilhelm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Runge, MD</last_name>
      <phone>33 2 38 51 44 44</phone>
      <email>isabelle.runge@chr-orleans.fr</email>
    </contact>
    <contact_backup>
      <last_name>Didier Poisson, MD</last_name>
      <email>didier.poisson@chr-orleans.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Didier Poisson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pointe à Pitre les Abymes</name>
      <address>
        <city>Pointe à Pitre</city>
        <zip>97159</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Thiery, MD, PhD</last_name>
      <phone>33 5 90 89 17 74</phone>
      <email>guillaume.thiery@chu-guadeloupe.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sylvaine Bastian, MD</last_name>
      <phone>33 5.90.89.12.69</phone>
      <email>sylvaine.bastian@chu-guadeloupe.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sylvaine Bastian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Poissy Saint Germain</name>
      <address>
        <city>Poissy</city>
        <zip>78600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Fangio, MD</last_name>
      <phone>33 1 39 27 52 05</phone>
      <email>pfangio@chi-poissy-st-germain.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mireille Cheron, MD</last_name>
      <email>mcheron@chi-poissy-st-germain.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Mireille Cheron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cedric Cleophax, MD</last_name>
      <phone>33 1 30 75 43 40</phone>
      <email>cedric.cleophax@ch-pontoise.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pascale Martres, MD</last_name>
      <email>pascale.martres@ch-pontoise.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pascale Martres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion, site de Saint Denis de la Réunion</name>
      <address>
        <city>Saint Denis de la Réunion</city>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lefort Yannick, MD</last_name>
      <phone>33 2 62 90 56 90</phone>
      <email>yannick.lefort@chu-reunion.fr</email>
    </contact>
    <contact_backup>
      <last_name>Olivier Belmond, MD</last_name>
      <email>olivier.belmond@chu-reunion.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier Belmond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Saint Nazaire</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Courouble, MD</last_name>
      <phone>33 2 72 27 80 00</phone>
      <email>p.courouble@ch-saintnazaire.fr</email>
    </contact>
    <contact_backup>
      <last_name>Olivier Lemenand, MD</last_name>
      <email>o.lemenand@ch-saintnazaire.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier Lemenand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferhat Mezziani, MD, PhD</last_name>
      <phone>33 3 88 11 67 68</phone>
      <email>ferhat.meziani@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Antoine Grillon, MD</last_name>
      <phone>33 3 69 55 15 82</phone>
      <email>antoine.grillon@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Antoine Grillon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours, site Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Garot, MD</last_name>
      <phone>33 2 47 47 38 55</phone>
      <email>garot@med.univ-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Philippe Lanotte, MD</last_name>
      <email>philippe.lanotte@univ-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe Lanotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Girou E, Buu-Hoi A, Stephan F, Novara A, Gutmann L, Safar M, Fagon JY. Airway colonisation in long-term mechanically ventilated patients. Effect of semi-recumbent position and continuous subglottic suctioning. Intensive Care Med. 2004 Feb;30(2):225-233. doi: 10.1007/s00134-003-2077-4. Epub 2003 Nov 29.</citation>
    <PMID>14647884</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventilator-associated pneumonia</keyword>
  <keyword>Surveillance</keyword>
  <keyword>Subglottic-secretions</keyword>
  <keyword>Critically ill patients</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

